Bimatoprost is a prostaglandin analog indicated for the reduction of intra-ocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is supplied as a sterile ophthalmic solution in a 3 ml bottle. In Hong Kong, the product is regulated by the Department of Health’s Drug Office and is available by prescription only.
Bimatoprost mimics the activity of naturally occurring prostaglandins. After a single drop is instilled into the eye, it binds to prostaglandin-F (FP) receptors in the ocular tissues. This interaction increases the outflow of aqueous humor through both the trabecular meshwork and the uveoscleral pathway, leading to a gradual reduction in IOP. The onset of pressure-lowering effect typically occurs within a few hours, with peak efficacy reached after 8-12 hours. Because the drug is administered locally, systemic absorption is minimal, limiting systemic side effects.
These indications are approved by the Hong Kong Department of Health and are reflected in the product’s prescribing information.
Patients should disclose all eye drops, oral medications, supplements, and herbal products to their eye care professional before initiating bimatoprost.
This article provides educational information about Bimatoprost and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Evening dosing is recommended because prostaglandin analogs have a greater IOP-lowering effect during nocturnal hours, and bedtime administration may reduce the incidence of transient ocular irritation.
Yes, the medication can be instilled in each affected eye once daily, unless directed otherwise by the prescribing clinician.
Conjunctival hyperemia is a common, usually mild side effect caused by vasodilation of the eye’s superficial blood vessels. It often diminishes with continued use.
Transient blurred vision can occur immediately after drop instillation due to the solution’s viscosity. Blurred vision typically resolves within a few minutes.
Patients should remove contact lenses before instilling the drop and wait at least 15 minutes before reinserting them to avoid lens contamination and irritation.
Combination therapy is possible, but certain agents (e.g., other prostaglandin analogs) may increase side-effect risk. Coordination with an eye care professional is essential.
Bimatoprost can lengthen and darken eyelashes, a property exploited in a cosmetic formulation marketed separately. This effect is considered an incidental, non-therapeutic outcome when using the ophthalmic solution.
A measurable decrease in IOP is typically observed within 4 hours of the first dose, with maximal effect achieved after several weeks of consistent daily use.
Severe pain may indicate a serious adverse event such as iridocyclitis or an infection. Seek immediate ophthalmic evaluation or attend the nearest emergency department.
Coverage depends on the patient’s eligibility under the Hong Kong Hospital Authority or private insurance plans. Patients should verify reimbursement details with their healthcare provider or insurer.
